ASCO 2014: Highlights beim Kolorektalkarzinom: Erstlinientherapie, Erhaltungstherapie, BRAF-Mutation

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Ass.-Prof. Dr. Martin Pichler

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, USA


AutorIn: Assoz.-Prof. Priv.-Doz. Dr. Armin Gerger

Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin, Comprehensive Cancer Center Graz, Medizinische Universität Graz


1 Schwartzberg LS et al., PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol 2014 Apr 21 [Epub ahead of print]

2 Stintzing S et al., Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer patients. ECC 2014; Abstract LBA17

3 Koopman M et al., Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer. ASCO GI 2014; LBA388

4 Falcone F et al., FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer patients: Results of the phase III TRIBE trial by GONO group. ASCO 2013; LBA 3505


SO 03|2014

Herausgeber: Univ.-Prof. Dr. Christoph Zielinski, Univ.-Prof. Dr. Markus Raderer
Publikationsdatum: 2014-11-07